Osimertinib vs Zorifertinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline

Osimertinib · Tagrisso

Marketed by AstraZeneca

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT02151981 · Phase 3 · completed

The trial was randomized and actively controlled, with 279 patients receiving osimertinib and 140 receiving platinum-based chemotherapy, but treatment assignment was not blinded. Its primary clinical endpoint, investigator-assessed progression-free survival, favored osimertinib significantly (hazard ratio 0.30; p<0.001), supporting moderate-strength evidence rather than the strongest level because the study was open-label.

Next expected readout: November 2026 · NCT05998993 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6) (met)

Result source: NCT02151981

Zorifertinib

Marketed by Alpha Biopharma (Jiangsu) Co., Ltd. and partners

Phase 2/3 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT03653546 · Phase 2/3 · completed

The trial randomized 492 participants to AZD3759 or active treatment with erlotinib or gefitinib, with progression-free survival assessed by independent central radiology as the primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: May 2027 · NCT07551414 (registry estimate)

Reported efficacy

PFS assessed by Blinded Independent Central Radiological (48 months): Median PFS by blinded independent central review: 9.6 months (zorifertinib/AZD3759) vs 6.9 months (control, gefitinib or erlotinib); HR 0.719 (95% CI 0.580-0.893), p=0.0024 (met)

Result source: NCT03653546

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointOsimertinibZorifertinib
PFS, median19.5 vs 22.0vs Gefitinibn 45NCT02856893
1 other result
9.6 vs 6.9avs control, gefitinib or erlotinibNCT03653546
OS, median—Not posted · NCT05015608—Not posted · NCT03653546
ORR76%bn 25NCT02789345—Not posted · NCT03653546
Duration of response, median13.4bn 19NCT02789345—Not posted · NCT03653546

PFS, median

Osimertinib
19.5 vs 22.0vs Gefitinibn 45NCT02856893
1 other result
Zorifertinib
9.6 vs 6.9avs control, gefitinib or erlotinibNCT03653546

OS, median

Osimertinib
—Not posted · NCT05015608
Zorifertinib
—Not posted · NCT03653546

ORR

Osimertinib
76%bn 25NCT02789345
Zorifertinib
—Not posted · NCT03653546

Duration of response, median

Osimertinib
13.4bn 19NCT02789345
Zorifertinib
—Not posted · NCT03653546
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  3. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  4. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Osimertinib: 4 of 4 rows · Zorifertinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOsimertinibZorifertinib
Dropout rate
62.3%a
NCT02856893 · Phase 2 · registry result, not featured evidence
show 2 more results
100%Arm A: Ramucirumab + Osimertinib
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
77.3%Cohort A: Ramucirumab + Osimertini
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
—
Discontinued due to AEs
3.8%a
NCT02856893 · Phase 2 · registry result, not featured evidence
show 2 more results
0%Arm A: Ramucirumab + Osimertinib
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
4.5%Cohort A: Ramucirumab + Osimertini
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
—
Serious AEs
17%a
NCT02856893 · Phase 2 · registry result, not featured evidence
show 2 more results
33.3%Arm A: Ramucirumab + Osimertinib
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
36.4%Cohort A: Ramucirumab + Osimertini
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
—
Most frequent reported AEs
a
diarrhea 50.9%
dry skin 41.5%
weight loss 35.8%
NCT02856893 · Phase 2 · registry result, not featured evidence
show 2 more results
cough 100%
diarrhoea 100%
arthralgia 66.7%
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
diarrhoea 63.6%
hypertension 63.6%
decreased appetite 40.9%
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
—

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Osimertinib

PFS18 51.1% (n=45) vs 67.2% (n=47) Gefitinib @ 78wk
responder rate · % of participants
NCT02856893 · Phase 2 · registry result, not featured evidence
Time to Progression 19.48 vs 10.81 Gefitinib months
time to event · months
NCT02856893 · Phase 2 · registry result, not featured evidence
ORR 0.889 vs 0.656 Gefitinib count
event count · count
NCT02856893 · Phase 2 · registry result, not featured evidence
Overall Survival NA vs NA Gefitinib months
time to event · months
NCT02856893 · Phase 2 · registry result, not featured evidence
Intracranial PFS 34.3 vs 24.44 Gefitinib months
absolute value · months
NCT02856893 · Phase 2 · registry result, not featured evidence
PFS2 25.76 vs 21.98 Gefitinib months
time to event · months
NCT02856893 · Phase 2 · registry result, not featured evidence
ORR 76% (n=25)
responder rate · % of participants
No placebo or comparator arm
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Disease Control 92% (n=25)
responder rate · % of participants
No placebo or comparator arm
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Duration of Response 13.37 months
time to event · months
No placebo or comparator arm
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
PFS 11.04 months
time to event · months
No placebo or comparator arm
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Overall Survival NA months
time to event · months
No placebo or comparator arm
NCT02789345 · Phase 1 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Osimertinib's landscape · Zorifertinib's landscape